NanoBrick is showing strong performance. As the number of COVID-19 variant virus infections rapidly increases worldwide, the company's core nucleic acid extraction reagent for molecular diagnostics, M-Bead, appears to be gaining attention.
As of 2:40 PM on the 8th, NanoBrick was trading at 1,700 KRW, up 96 KRW (5.99%) compared to the previous trading day.
According to the Korea Disease Control and Prevention Agency on the 7th of this month, the number of COVID-19 hospitalized patients has surged 5.1 times over the past four weeks. The number of new COVID-19 hospital admissions surveyed at 220 sample surveillance institutions nationwide with hospitals of 200 beds or more was 91 in the first week of July, 148 in the second week, 225 in the third week, and 465 in the fourth week.
As a result, sales of self-diagnostic test kits are also increasing. According to statistics from CareInsight, a pharmacy data analysis service, sales of COVID-19 self-diagnostic test kits increased by 43.8% from July 21 to 27 compared to the previous week.
NanoBrick's M-Bead is a magnetic bead material, a key raw material for nucleic acid separation and purification reagents in the bio industry. Superparamagnetic nanoparticles are coated with functional groups, enabling rapid and selective separation of biological substances. Unlike traditional methods that required more than 30 minutes of purification time using centrifuges, the magnetic bead method allows for easy processing of large volumes of samples in a short time using magnets. M-Bead is mainly used in diagnostic kits and new drug development.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
